Cellosaurus logo
expasy logo

Cellosaurus Evsa-T (CVCL_1207)

[Text version]
Cell line name Evsa-T
Synonyms EVSA-T; EVSa-T; EVSA/T; Evsa T; EVSAT; EvsaT
Accession CVCL_1207
Resource Identification Initiative To cite this cell line use: Evsa-T (RRID:CVCL_1207)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JWGray breast cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Doubling time: 25 hours (PubMed=9488600); ~50 hours (DSMZ=ACC-433).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Mutation; HGNC; HGNC:1748; CDH1; Simple; c.687+1_687+2delGT; ClinVar=VCV000483268; Zygosity=Homozygous (PubMed=19593635).
  • Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.951_954delACTT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (PubMed=19593635).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (PubMed=16541312; Cosmic-CLP=906862).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.86
Native American1.1
East Asian, North2.9
East Asian, South0
South Asian8.5
European, North19.45
European, South67.19
Disease Breast carcinoma (NCIt: C4872)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A1FL (Evsa-T GDC-0941-resistant clone 1)
Originate from same individual CVCL_5G37 ! Evsa-E
Sex of cell Female
Age at sampling 58Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=906862; DSMZ=ACC-433; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D2S133824
D3S135814,17
D5S81812,13
D7S82010,12
D8S117916
D13S31711,12 (Cosmic-CLP=906862; DSMZ=ACC-433)
12 (PubMed=25877200)
D16S5399
D18S5112,17
D19S43313
D21S1130,31.2
FGA21,24,25
Penta D12,14
Penta E12,16
TH016
TPOX8
vWA15,16

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
https://tcpaportal.org/mclp/
Publications

PubMed=1000504
Lippman M.E., Bolan G., Huff K.
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4595-4601(1976)

PubMed=1000505
Lippman M.E., Bolan G., Huff K.
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4602-4609(1976)

PubMed=212193
Engel L.W., Young N.A.
Human breast carcinoma cells in continuous culture: a review.
Cancer Res. 38:4327-4339(1978)

PubMed=3702420; DOI=10.1016/0022-4731(86)90083-X
Devleeschouwer N., Olea-Serrano N., Leclercq G., Legros N., Heuson J.-C.
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line.
J. Steroid Biochem. 24:365-368(1986)

PubMed=9570382; DOI=10.1016/S0304-3835(97)00285-1
Borras M., Lacroix M., Legros N., Leclercq G.
Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers.
Cancer Lett. 120:23-30(1997)

PubMed=9488600; DOI=10.1007/s002800050744
Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G., Schellens J.H.M.
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Cancer Chemother. Pharmacol. 41:307-316(1998)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A.F.A.S., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201
Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y., Hampton G.M., Lackner M.R.
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Cancer Res. 76:1193-1203(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) DSMZ; ACC-433
Cell line databases/resources CLO; CLO_0002955
cancercelllines; CVCL_1207
Cell_Model_Passport; SIDM01042
Cosmic-CLP; 906862
DepMap; ACH-001065
DSMZCellDive; ACC-433
LINCS_LDP; LCL-1313
TOKU-E; 4049
Biological sample resources BioSample; SAMN03472910
BioSample; SAMN03473598
BioSample; SAMN10988228
CRISP screens repositories BioGRID_ORCS_Cell_line; 885
Chemistry resources ChEMBL-Cells; CHEMBL3307361
ChEMBL-Targets; CHEMBL614295
GDSC; 906862
PharmacoDB; EVSAT_349_2019
PubChem_Cell_line; CVCL_1207
Encyclopedic resources Wikidata; Q54832986
Experimental variables resources EFO; EFO_0006574
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
GEO; GSM274650
GEO; GSM344366
GEO; GSM344416
GEO; GSM421866
GEO; GSM783964
GEO; GSM843500
GEO; GSM843501
GEO; GSM847317
GEO; GSM847471
GEO; GSM1172953
GEO; GSM1374477
GEO; GSM1661978
GEO; GSM1669780
Polymorphism and mutation databases Cosmic; 906862
Cosmic; 944298
Cosmic; 997931
Cosmic; 1046926
Cosmic; 1287906
Cosmic; 1289388
Cosmic; 2165020
Cosmic; 2750518
Cosmic; 2787554
IARC_TP53; 24357
Progenetix; CVCL_1207
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number43